Efficacy and safety of Xinkeshu combined with conventional antihypertensive therapy for left ventricular hypertrophy in patients with hypertension:a meta analysis
Objective To evaluate the efficacy and safety of Xinkeshu combined with conventional antihypertensive regi-men in the treatment of left ventricular hypertrophy(LVH)in patients with hypertension through meta-analysis.Methods A systematic literature search was conducted on the randomized controlled trial(RCT)of Xinkeshu combined with conventional antihypertensive regimen for LVH in hypertension from the establishment of CNKI,Wanfang,VIP,SinoMed,PubMed,EM-base,the Web of Science,and Cochrane Library databases until September 2022.Data extraction and bias risk assessment were conducted after literature screening by two independent researchers,and meta-analysis was performed with RevMan 5.4 software.Results 9 studies were ultimately identified,involving 797 patients.Meta analysis showed that compared with conventional antihypertensive regimen,Xinkeshu combined with conventional antihypertensive therapy could significantly im-prove ventricular septal thickness(IVST)(MD=-1.33,95% CI[-1.87,-0.79],P<0.00001),left ventricular posterior wall thickness(LVPWT)(MD=-1.64,95% CI[-1.96,-1.32],P<0.00001),left ventricular mass index(LVMI)(MD=-7.60,95% CI[-10.25,-4.95],P<0.00001),systolic blood pressure(SBP)(MD=-17.73,95% CI[-23.11,-12.34],P<0.00001),diastolic blood pressure(DBP)(MD =-10.55,95% CI[-14.07,-7.04],P<0.00001),left ventricular ejection fraction(LVEF)(MD=3.60,95% CI[1.24,5.95],P=0.003),and left ventricular end diastolic diameter(LVEDD)(MD=-2.03,95% CI[-2.58,-1.48],P<0.00001).There was no statistically signifi-cant difference in the incidence of adverse reactions between the two groups(RR= 0.86,95% CI[0.24,3.04],P= 0.82).In terms of safety,there were no serious adverse events,and the clinical application has good safety.Conclusion The therapeutic effect of Xinkeshu combined with conventional antihypertensive regimen of Western medicine on left ventricu-lar hypertrophy in patients with hypertension is superior to that of conventional antihypertensive regimen alone to some extent,with good safety.
万方数据
维普
